Actively Recruiting
Effects of Personalized Reminiscence Sessions Delivered by a Digital Conversational Agent to Patients With Neurocognitive Disorders
Led by KompanionCare SAS · Updated on 2026-03-09
80
Participants Needed
5
Research Sites
N/A
Total Duration
On this page
Sponsors
K
KompanionCare SAS
Lead Sponsor
C
Clinical Research Units Hungary
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of daily personalized digital reminiscence therapy on patients with early-stage neurocognitive disorders or mild cognitive impairment. The study aims to determine if daily sessions using a digital conversational agent can improve symptoms like apathy and depression, as well as enhance aspects of well-being such as motivation, mood, sleep quality, quality of life, and engagement. It also investigates whether simple reminders through the app can encourage regular use without external help. Participants will use a personalized reminiscence app for 10 to 15 minutes daily over 25 days. A primary caregiver helps personalize the app by sharing family memories, and other relatives may contribute in a private group. The study observes a single group exposed to this digital therapy without a comparison group. During the study, participants complete brief questionnaires at the start and during follow-up visits to assess apathy, depression, sleep quality, and quality of life. Researchers will measure changes in depression and apathy scores at baseline, day 25, and day 50. They will also track session completion and duration. The total participation includes initial use and follow-up assessments to monitor outcomes and engagement.
CONDITIONS
Brief Title
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women over 60 years of age.
- Diagnosed with early stage major neurocognitive disorders or mild cognitive impairment (MCI) according to DSM-5.
- Mini-Mental State Exam (MMSE) score between 21 and 28.
- Presence of mild or moderate depression, mild or moderate apathy, or both.
- Able to physically and cognitively interact with the digital tool without major limitations.
- Voluntarily agreed to participate and signed written consent.
- Able to hear and see the digital tool's stimuli.
- Access to an Apple smartphone or tablet running iOS 16 or higher with internet access.
- Has at least one close relative willing to contribute biographical information via the app's messaging group.
- Covered by a social security scheme.
You will not qualify if you...
- Moderate or severe dementia with MMSE score 20 or below.
- Major psychiatric disorders such as schizophrenia, severe major depression, or bipolar disorder.
- Significant hearing or visual impairments.
- History of intellectual disability prior to illness.
- Under guardianship, conservatorship, or legal protection.
- Previous use of the Lilia app.
- Participation in another clinical study or therapeutic trial during this study.
- Received new medication for neurocognitive disorders within 3 months before joining.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 50 days
Participants engage in daily 10 to 15 minute personalized digital reminiscence therapy sessions and are observed for changes in cognitive and emotional measures.
Assessments at baseline, Day 25, and Day 50
Trial Site Locations
Total: 5 locations
1
CHU Angers, Service médecine gériatrique.
Angers, France, 49 933
Actively Recruiting
2
Limoges University Hospital Center - Dupuytren Hospital], Geriatric medicine department
Limoges, France, 87042
Actively Recruiting
3
Centre Hospitalier Universitaire de Nice - Institut Claude Pompidou, Centre Mémoire de Ressources et de Recherches (CM2R)
Nice, France, 06100
Actively Recruiting
4
APHP Hôpitaux universitaires Paris centre.
Paris, France, 75013
Not Yet Recruiting
5
CHU DE TOURS, Pôle Vieillissement, Hôpital Bretonneau.
Tours, France, 37044
Actively Recruiting
Research Team
P
Peter MARKUS
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here